AbbVie Inc (ABBV)vsENvue Medical Inc. (FEED)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
FEED
ENvue Medical Inc.
$1.16
0.00%
HEALTHCARE · Cap: $4.96M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2395513% more annual revenue ($61.16B vs $2.55M). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
FEED
Avoid30
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Margin of Safety
+8.4%
Fair Value
$2.96
Current Price
$1.16
$1.80 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -106.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : FEED
The strongest argument for FEED centers on Price/Book.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : FEED
The primary concerns for FEED are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
FEED carries more volatility with a beta of 2.10 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ENvue Medical Inc.
HEALTHCARE · MEDICAL DEVICES · USA
ENvue Medical Inc. (FEED) is an innovative healthcare technology company dedicated to transforming patient care management with its advanced medical devices and comprehensive software solutions. By leveraging cutting-edge technology, ENvue Medical aims to enhance recovery processes and elevate health outcomes in diverse clinical environments. Its promising product pipeline, along with strategic partnerships, uniquely positions the company to seize the expanding opportunities within the healthcare sector, making it an attractive investment prospect for institutional investors focused on the evolving landscape of medical device innovation and digital health.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?